Member Info for Merchantbanker

Spot on Safy

DOH - Mologic have their own manufacturing facility capable of producing 40m per year. They also have a $20m grant from Gates. They do not need to commence tech transfer to themselves. As soon as they CE mark it they can get the production line up and running. Yes it will take 1 month for ODX to transfer the tech. They completed the tech transfer of YUK RTC and Mologic antibody tests in 1 month. They have a proven track record. Lets say for a second it was Avacta's test if they had a test, wouldn't it still take the same time anyway so the argument is floored.

How can you say tech transfer takes 4 weeks so it must be Avacta's. If it was avactas wouldn't that take the same amount of time for TT?!!?!! The desperation from AVCT shareholders for every mention of Antigen tests to be theirs is understandable when you have a £450m valuation with no test.

Yeah but that evidence is based on tech transfer without an actual test so of course it wont happen in a month. ODX have already achieved tech transfer in 1 month with the 2 antibody tests. Better to back those with a track record.

Yeah agree was a cracking presentation. Several credible revenue streams, with high margins. Omega are in a fantastic position. Our risk is being managed very well and there is significant upside for new investors.

He said tech transfer commence end of Nov to complete by xmas, as anyone that actually listened to the presentation will confirm.

Mologic have their own manufacturing facility. They expected to CE mark it by the end of Oct. TT by ODX is not the limiting factor, it is CE mark by Mologic.

No it is not your Avacta "test" it is the Mologic test as the presentation says.

Mologic - Mologic will go live with the test and announce CE mark before we start tech transfer, obviously.

3rd party sales - additional profit share!!!! Big news!!! £££

rob smith - only in cloud cuckoo land

This is confirming we expect an announcement on a UK lateral flow antigen test in the next 4 weeks maximum. Huge news for this country.

Not much else to say other than header. Short term share price declines do not reflect the potential here.

In house laboratory testing coming for antibody Elisa - new revenue streams. Higher returns.

November capacity already committed to demand

Very dangerous tactics quoting markets sizes in the billions expecting to take a share when you have nothing commercial to offer.

Affimers were launched in 2014 and haven't led to a single commercial product yet. Funny how the single biggest market opportunity there has ever been and all of a sudden Avacta are going to save the world. I really just don't buy it. 6 years of nothing, it will be another 6 years of nothing IMO. Alistair smith has been quoting markets worth billions since 2014 as per below.

https://www.drugtargetreview.com/news/1763/avacta-life-sciences-takes-55bn-antibody-market-launch-affimers/

Any other directors moving house?

Timster - correct. One makes and sells tests.

Our test vs your test aside...... you really need to consider the fact that AVCT may never get a commercial test to market.

Yes Mologic are looking to develop a test that can sell to lower income countries as cheap as possible. They have set up a separate non commercial enterprise Global Access Diagnostics with 40m per year capacity. GAD will satisfy the low income market. Gates have just made over $20m donation to help fund it. What ODX have is the same tech with the ability to commercialise in their own brand to more suitable markets for commercial opportunity.

Affimers have never led to a commercial test and it is clear from AS comments that sensitivity is a problem. If all other tests have the same problem, AVCT may be ok, but if they cant get a sensitive enough test and others can, then the test will never get off the ground. It's clear despite the testing shortfall that regulators are not prepared to rush through tests, and the fact that affimers are an unknown quantity isn't going to help.

I don't really care what people choose to believe, as i've said before if MCAP was £50m i'd say it's about right for the level of risk. This is priced with 90% chance of success, where in reality i would say its more like 25% max. I hope for your sakes they do pull it off, but i think it's starting to look less likely.

Grumpy - not really. Topped up at a very decent price, finally convinced me to sell another stock i was hoping to hold onto.

Take a good look at it because that 15% drop over there will look like a feather floating down from the top of a building compared to what it will look like here when AS has to come clean that they can't produce a test up to the required standard.

Callum - not a cross ramp. Just fact, i don't care if anyone here buys over there or not. Perspective regarding what it actually takes to get a quality test to market. Mologic expect to CE mark any day, Avacta haven't even got a test that they are confident enough to put into clinical validation yet. Don't worry though, AS put CONDOR in an RNS.

Thanks for the awakening Arbitrage. A poor day all over the markets, ODX getting hammered massively oversold and without good reason. At least ODX have actual products that can turn into sales and profit eventually. It just shows having a potential test and actually getting it commercialized and then seeing financial impact isn't straightforward. Especially if you don't have a test.
Mologic Antigen test is just days away from being CE marked. It will be the first available Antigen test in the UK by the looks of it. Mologic have proven success in delivering tests. I would rather have 1 bad day over there now because of impatient traders that rather have hyped up promises to suite their trades than an actual credible business plan, than sit here praying that somehow AVCT can pull off a test. I finally managed to check out the Q&A here last night, didn't do anything other than confirm my suspicions this is all smoke and mirrors and there will never be a test on the market. At least AS has a new house, perhaps he will invite all his shareholders round for a summer bbq next year to apologize.

And by the way the difference with ODX tech transfer is they are doing tech transfer after the product is approved, not before.